Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Reports 6% Q4 Revenue Growth

Published: Friday, January 31, 2014
Last Updated: Friday, January 31, 2014
Bookmark and Share
Thermo Fisher Scientific Inc. reported its financial results for the fourth quarter and full year ended December 31, 2013.

Fourth Quarter and Full Year 2013 Highlights

  • Grew full year adjusted earnings per share (EPS) by 10% to a record $5.42, and fourth quarter adjusted EPS by 5% to a record $1.43.
  • Increased fourth quarter revenue by 6% to a record $3.47 billion.
  • Expanded adjusted operating margin in the fourth quarter by 40 basis points to 20.0%.
  • Generated free cash flow of $1.75 billion for the full year.
  • Launched innovative new Thermo Scientific products during the year to strengthen leading mass spectrometry, chromatography, specialty diagnostics and biosciences offerings, highlighted by the breakthrough Orbitrap Fusion Tribrid and new triple-quad platforms.
  • Achieved 20% growth in China for the year by leveraging investments to expand R&D, manufacturing and commercial capabilities, and delivered strong results in other high-growth markets, including Korea and Brazil.
  • Returned more than $300 million of capital to shareholders through stock buybacks and dividends.
  • Acquiring Life Technologies to add complementary genomics, next-generation sequencing and forensic science capabilities for customers in life sciences and applied markets, and to expand presence in APAC and emerging markets.

Adjusted EPS, adjusted operating income, adjusted operating margin and free cash flow are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”

“Our teams executed very well in the quarter to achieve outstanding results on both the top and bottom line,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “All three business segments reported solid growth, and drove productivity to deliver 40 basis points of adjusted operating margin expansion. Our excellent operating performance throughout 2013 extended our track record of delivering strong adjusted EPS growth, and led to a 10% increase for the full year.

“These results demonstrate the success of our growth strategy and our ability to further differentiate Thermo Fisher in the markets we serve. We strengthened our innovation leadership by launching new products across our portfolio for customers in research, bioproduction, specialty diagnostics and applied markets. We also leveraged our scale and depth of capabilities to help our customers in high-growth emerging markets respond to the need for better air quality, safer food supplies and growing demand for specialty diagnostics.

“Last, we look forward to completing our acquisition of Life Technologies, which will enhance our unique customer value proposition by broadening our product offering and adding another premier life sciences brand. We’re excited about the new opportunities we will have by combining our genomics, proteomics and specialty diagnostics technologies to help our customers accelerate results and improve human health.”

Fourth Quarter 2013
For the fourth quarter of 2013, adjusted EPS grew 5% to $1.43, versus $1.36 in the fourth quarter of 2012. Revenue for the quarter grew 6% to $3.47 billion in 2013, versus $3.26 billion in 2012. Organic revenue growth was also 6% as the effects of acquisitions and currency translation were immaterial. Adjusted operating income for the fourth quarter of 2013 increased 9% compared with the year-ago period, and adjusted operating margin expanded to 20.0%, compared with 19.6% in the fourth quarter of 2012.

GAAP diluted EPS for the fourth quarter of 2013 was $0.92, versus $1.04 in the same quarter last year. The 2012 period included a favorable impact related to a tax rate change in a foreign jurisdiction. GAAP operating income for the fourth quarter of 2013 increased 14% to $455 million, compared with $401 million in 2012. GAAP operating margin increased to 13.1%, compared with 12.3% in the fourth quarter of 2012.

Full Year 2013
For the full year 2013, adjusted EPS grew 10% to $5.42, versus $4.94 in 2012. Revenue for 2013 grew 5% to $13.09 billion, versus $12.51 billion a year ago. Organic revenue grew 3%; acquisitions increased revenue by 2% and currency translation had a nominal impact. Adjusted operating income for 2013 increased 7% compared with 2012, and adjusted operating margin expanded to 19.5%, compared with 19.0% a year ago.

GAAP diluted EPS for 2013 was $3.48, versus $3.21 in 2012. GAAP operating income for 2013 increased 9% to $1.61 billion, compared with $1.48 billion a year ago. GAAP operating margin increased to 12.3%, compared with 11.8% in 2012.

Annual Guidance for 2014
Casper added, “Our excellent performance in 2013 positions us well for the year ahead. We look forward to successfully integrating Life Technologies and fully leveraging our depth of capabilities to create value for our customers and achieve our goals for growth in 2014.”

Thermo Fisher is initiating adjusted EPS and revenue guidance for the full year 2014. The company expects to achieve adjusted EPS in the range of $6.70 to $6.90 for 2014, which would result in 24% to 27% adjusted EPS growth over 2013. The company expects to achieve 2014 revenue in the range of $16.63 billion to $16.83 billion, for 27% to 29% revenue growth year over year.

The company’s 2014 guidance includes the results of Life Technologies from an assumed close date, and includes the results of the previously announced divestitures through an assumed sale date. The guidance does not include any other future acquisitions or divestitures and is based on current foreign exchange rates. The adjusted EPS estimate excludes amortization expense for acquisition-related intangible assets and certain other items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Launches Geneticon
Thermo Fisher Scientific launches GenetiCon, a virtual resource showcasing the real-life science behind superheroic powers and more.
Tuesday, July 07, 2015
Thermo Fisher Agrees to Buy Alfa Aesar for $403M
The company announced a definitive agreement to buy the research chemical manufacturer for $403 million.
Friday, June 26, 2015
Ebola Sequencing Data Released to Global Research Community Online
To curb further spread of Ebola in Sierra Leone, a team of scientists that is part of an international, multi-organizational effort has released their first dataset of the virus’ genetic structure online.
Wednesday, June 03, 2015
Thermo's NGS Platform Selected for Nationwide Clinical Research Program
National Cancer Institute-MATCH trial to sequence thousands of tumor samples using Ion Torrent targeted sequencing technology.
Monday, June 01, 2015
Thermo Strengthens Bioprocessing Offering with Advanced Scientifics Acquisition
Thermo Fisher Scientific has acquired Advanced Scientifics, Inc., a global provider of single-use technologies for customized bioprocessing solutions, for $300 million in cash.
Friday, February 06, 2015
Thermo Fisher Q3 Revenues up 31 Percent
Thermo Fisher announced that revenues grew 31% to $4.17 billion for the third quarter ended September 27, 2014.
Thursday, October 23, 2014
Thermo Scientific Announces Listing of the Ion PGM Dx System
Company has completed the listing with the U.S. FDA as class II medical device.
Saturday, September 20, 2014
Thermo Fisher, NRLs Team to Confirm Dioxins in Feed and Food
Thermo Fisher Scientific worked closely with national reference labs (NRLs) in the European Union to support the development of new regulation.
Monday, September 08, 2014
Thermo Completes Sale of Cole-Parmer to GTCR
Thermo Fisher Scientific Inc. announced that it has completed the sale of its Cole-Parmer customer channel business to private equity firm GTCR LLC for approximately $480 million in cash.
Wednesday, August 20, 2014
Thermo Supports Distinguished Analytical Chemistry Seminar Series at NC State
An endowment established by the company provides opportunities to attend presentations by leading analytical chemistry authorities.
Tuesday, August 19, 2014
NSF International Expands Use of Thermo Scientific Watson LIMS
NSF International implements Thermo Scientific Watson LIMS to support bioanalytical testing for both clinical and non-clinical research studies at Bristol, CT laboratory.
Saturday, August 09, 2014
Thermo, NewLab Sign Forensic Sample Processing Distribution Agreement
Under the agreement, Thermo Fisher is the sole distributor and servicing agent of the CPA300™ and CPA200™ card processing instruments.
Friday, July 25, 2014
Thermo to Sell Cole-Parmer for $480M
Company has signed a definitive agreement to sell its Cole-Parmer channel business to private equity firm GTCR, LLC for $480 million in cash.
Monday, July 21, 2014
Reimagining UHPLC
To learn more about the new Vanquish UHPLC system from Thermo Fisher Scientific we spoke to Wulff Niedner, Director of HPLC Product Marketing.
Thursday, July 17, 2014
ATCC, CDC and Thermo Partner on Public Health RT-PCR Assay
New technology supports HIV-1 drug resistance surveillance in resource-limited countries.
Wednesday, June 25, 2014
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!